This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
The commissioner of the Food and Drug Administration has announced in a Notice of Intent in the Federal Register (Vol 43, No. 31, Feb 14,1978) that he is planning to develop recommendations on the use of radiation for the treatment of benign diseases. These recommendations would apply to all disciplines of medicine that use ionizing radiation therapy (not only to dermatologists).
The FDA seeks information on the use, effectiveness, and risks of radiation therapy in the treatment of benign diseases. Interested physicians are invited to participate in the development of recommendations by submitting written comments, views, and data on this subject to the Hearing Clerk (HFC-20) Food and Drug Administration, Room 4-65, 5600 Fishers Lane, Rockville, MD 20857. The planned recommendations will be based on the results of a study of the current use of ionizing radiation in the treatment of benign diseases, which was recently conducted for FDA by
Goldschmidt H. Food and Drug Administration Recommendations on Radiation of Benign Diseases. Arch Dermatol. 1978;114(8):1149. doi:10.1001/archderm.1978.01640200003001
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: